DR.REDDY'S LABORATORIES LTD. Q1 FY27 Results

Dr Reddy's opened FY27 with a sharp year-on-year profit fall that its records-basis consolidated print makes plain: net profit after tax dropped 69% to ₹435.6 Cr (₹444.3 Cr attributable to the parent on IFRS) on revenue of ₹8,099.8 Cr, down 5.5% YoY. The eye-catching +97% QoQ profit jump is a base artifact — Q4FY26's ₹221 Cr was itself depressed by CAR-T, Immutep and VAT one-offs — and must not be read as momentum; year-on-year is the real story, and it is one of margin normalisation after the extraordinary Lenalidomide-driven Q1FY26 (NPM 15.9% then vs ~5.4% now). Net margin compressed hard on two counts: the structural roll-off of high-margin US Lenalidomide (North America revenue −35% YoY to ₹2,204.8 Cr) and a ₹239.7 Cr provision for out-of-spec semaglutide API batches that alone shaved ~3% off gross, EBITDA and PBT margins. Gross margin fell to 46.5% (49.4% ex-semaglutide) from 56.9% a year ago.

Against the Street, this is a clear miss — brokerage previews (Goodreturns) modelled PAT down ~40% and EBITDA down ~35%, but reported PAT fell 69% and management flagged the semaglutide charge as unexpected; multiple desks noted the print undershot on revenue, EBITDA and profit. Against management's own last-call guidance the read is mixed: the guided gross-margin 'reset to 50-55%' as Lenalidomide concludes has not yet been reached (46.5%, or 49.4% adjusted), so that checkpoint is missed for now; but the India 15%+ growth target was met (India revenue +17% YoY to ₹1,717.7 Cr, outperforming IPM), and the near-term semaglutide launch that guidance hinged on did happen (India tablets, Canada injection) — only for the API quality issue to delay supply and dent the P&L. Even adjusting for the ₹239.7 Cr one-off, underlying PAT of ~₹624 Cr is still down ~56% YoY, confirming this is a genuine earnings reset, not a cosmetic dip: the verdict is weak on adjusted growth, not merely optically hit.

The stock went into the print at ₹1,151.7, down 13.3% over the past month of trading.

PBT ₹553.3 Cr (−71% YoY) — tax ₹117.7 Cr at a low 21.3% ETR due to reversal of prior-year tax provisions; EBITDA margin 12.5% (15.4% ex-semaglutide).

The quarter's board actions sit alongside the numbers rather than moving them: the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics reinforces the biosimilar/Abatacept pipeline management is banking on for long-term value, and Deloitte's appointment as US registered auditor is housekeeping. Management's framing — G V Prasad calling it 'the expected transition beyond lenalidomide' with 'healthy double-digit base-business growth across geographies' plus 'an unexpected semaglutide API impact' — squares with the segment data (Emerging Markets +31%, Europe +13%, India +17% YoY), but the headline profit and margin damage is real and the base business alone does not yet offset the Lenalidomide and semaglutide drags.